Sugoi & Yokunai

This study demonstrates that brain aging follows a specific progression, with the first stage occurring in middle age and coinciding with increased insulin resistance. Moreover, we show that brain areas that age fastest are also those most vulnerable to neuronal insulin resistance. Importantly, we find that administering ketones, which can fuel neurons while bypassing insulin resistance, reverses brain aging effects. However, this intervention is only effective when provided early enough for neurons to remain viable. 

Ketones, whether produced endogenously through fasting or low-carbohydrate/high-fat diets or administered exogenously as a supplement, have been shown to improve age-related cognitive decline and to restore insulin-resistance-induced deficits in axonal conduction velocity. Moreover, ketones may improve neural functioning even at baseline, strengthening signaling for neurons without being compromised by insulin resistance and across the brain for younger individuals in their 20s and 30s. This increased metabolic efficiency under ketosis is consistent with effects reported for other organs, such as the heart.

The 5-year disease-free survival was 80.3% in the exercise group and 73.9% in the health-education group. 

The 8-year overall survival was 90.3% in the exercise group and 83.2% in the health-education group. 

“authentic inquiries into science through embodied learning approaches can provide rich opportunities for sense-making through kinesthetic experience, embodied imagining, and the representation of physics concepts for Black and Latinx teens when learning approaches focused on dance and dance-making.”

“... Defendants fail to articulate why words strung together by (Large Language Models, or LLMs, trained in engaging in open dialog with online users) are speech. ... The court is not prepared to hold that Character.AI's output is speech.”

Moderna's low-dose COVID vax got approved by the FDA.  I wanted to learn more about this new Moderna vax, referred to as mRNA-1283.  Guess what?  There's no published peer-reviewed data on it! 
Yup, Moderna just supposedly sent their internal data to the FDA, and that was good enough.

There is published data from a phase 1 study from 2023, which is only powered to study safety, not efficacy. For that, you need a phase 2 study.
A phase 2a study came out only two months ago. All it showed was that the mRNA-1283 could elicit antibodies against receptor-binding and N-terminal domains of SARS-CoV2.
It didn't show survival benefit or any kind of useful protection, which you usually need to see.
A phase 2a study is a small study designed to take a preliminary look at efficacy after you've established a safe dose from a phase I study. It determines whether to proceed to a phase 2b study which is better powered for efficacy determination.

But Moderna released a press statement last year that the new formulation was able to elicit antibody responses in phase 3 study. This hasn't been published for review.
Then in July 2024 they announced release of data showing that it was non-inferior to Spikevax, but when you click for data, it only goes to their investors page.

In a very recent letter to the editor, it was pointed out that the mRNA-1283 data does not really show "vaccine effectiveness" as is generally understood, and that there are methodologic deficiencies in the existing studies. 

So, no transparency. We're supposed to just accept that this is another "safe and effective" vaccine. And the media dutifully promotes it like obedient sheep, without any questions of how this new low-dose vax was tested and shown to be worthy of approval.

Portland State’s engineering professor Bob Bass said the words diversity, equity and anti-racism appeared frequently in the titles and descriptions of canceled research programs.

Those likely took the largest cuts because the programs often expanded access to science learning, targeting underrepresented students, Bass said, in fields that remain overwhelmingly white, Asian and male.